Sangamo plunges after pricing stock offering; principal financial officer exits
Source: SeekingAlpha
2026-02-03 11:03:10 ET
More on Sangamo Therapeutics
- Sangamo Therapeutics, Inc. (SGMO) Q3 2025 Earnings Call Transcript
- Sangamo rises as FDA grants Fast Track status to neuropathic pain asset
- Sangamo rises as FDA accepts rolling submission request for gene therapy
- Seeking Alpha’s Quant Rating on Sangamo Therapeutics
- Historical earnings data for Sangamo Therapeutics
Read the full article on Seeking Alpha
For further details see:
Sangamo plunges after pricing stock offering; principal financial officer exits
Sangamo Therapeutics Inc.
NASDAQ: SGMO
SGMO Trading
-2.45% G/L:
$0.4018 Last:
727,425 Volume:
$0.4145 Open:
SGMO Latest News
March 09, 2026 08:05:00 am
Sangamo Therapeutics Advances Rolling Submission of BLA to U.S. FDA for ST-920 in Fabry Disease
February 03, 2026 04:05:00 pm
Sangamo Therapeutics Presents Detailed Data from Registrational STAAR Study in Fabry Disease at WORLDSymposium(TM) 2026
February 03, 2026 09:10:43 am
Sangamo Therapeutics Announces Pricing of $25.0 Million Underwritten Offering
December 18, 2025 08:05:00 am
Sangamo Therapeutics Initiates Rolling Submission of BLA to U.S. FDA for ST-920 in Fabry Disease
SGMO Stock Data
$133,083,570
322,698,215
1.31%
45
N/A
Biotechnology & Life Sciences
Healthcare
US
Richmond
